Answers are grounded in this paper and cite their sources.
It is estimated that there are approximately eight million new cases of active tuberculosis (TB) worldwide annually. There is only 1 vaccine available for prevention: bacillus Calmette-Guérin (BCG). This has variable efficacy and is only protective for certain extrapulmonary TB cases in children, therefore new strategies for the creation of novel vaccines have emerged. One of the promising approaches is the DNA vaccine, used as a direct vaccination or as a prime-boost vaccine. This review describes the experimental data obtained during the design of DNA vaccines for TB.
No takes yet. Share an insight, caveat, or question.
Rivas‐Santiago et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: